Epilepsy

Participate in an at-home COVID-19 antibody trial

Digital health trial overview

doc.ai is currently seeking participants for a research study, "Can A.I. predict the optimal anti-epileptic drug?"

doc.ai has partnered with the Epilepsy Foundation in a digital health trial that will include up to 1,000 participants and run from September 2019 through September 2020. Once enrolled via the doc.ai app, participants will keep an online diary tracking their seizure episodes and side effects of their medication for three months. Along with self-reported data, the study will collect and analyze participants’ health data, such as the genome (through a DNA test provided by Kailos), the phenome to capture physical traits, the physiome for activity, the pharmacome for medication tracking, and the exposome, which tracks environmental exposures.  

The study is conducted by Robert Fisher MD, PhD, Maslah Saul Professor and Director of the Stanford Epilepsy Center; Dennis Wall PhD, Associate Professor of Pediatrics, Psychiatry and Biomedical Data Sciences at Stanford Medical School and advisor at doc.ai; and Chethan Sarabu MD, Director of Clinical Informatics at doc.ai and physician at Stanford Medicine.


Why this health trial is important

Epilepsy, a neurological disorder characterized by unprovoked and recurrent seizures, affects 65 million people across the globe and 3.4 million in the U.S. 
Two thirds of people with epilepsy will gain good control of their symptoms with medications, but a third will not. While the cause of seizures is largely unknown, more than 25 medications have been developed to help manage symptoms. The process of drug selection is still largely a matter of trial and error. There are over 14,000 possible combinations of up to three drugs. Discovering which drugs are effective and which aren’t is a puzzle for clinicians and this is where A.I. may be helpful. Until the right medication combination is established, patients may suffer from severe side effects and adverse reactions, sometimes for years. 

 “We're excited to see continued advancement in the way we treat epilepsy,” said Sonya Dumanis, PhD, Senior Director of Innovation, Epilepsy Foundation. “The Digital Health Trial is another research milestone for our community as it has the potential to provide physicians and people with epilepsy with new options to optimize and personalize treatment. Our hope is that the use of A.I. to develop a predictive model to help identify the right approach for each person will help those struggling to gain better seizure control.” 

“doc.ai has a robust multi-omics data pipeline, and we’re proud to contribute DNA tests free of charge to advance medicine,” said Troy Moore, Chief Scientific Officer of Kailos Genetics, Inc. “We hope to see some indications of clinical utility for DNA testing and treating someone with a variety of types of epilepsy. It’s early days, and together we’re testing a model of focused delivery to different population groups, which could strengthen links between epilepsy and genetics and show downstream outcomes.” 


Protocol: DOC-002-2018
Can A.I. predict the optimal anti-epileptic drug?

Participation in this study will help advance medication research and contribute to a better understanding of epilepsy. Participants who complete this study will receive a visualization of their symptoms, an individualized report they can share with their doctor, and financial compensation for their time. Questions? Contact us at predictepilepsy@doc.ai. 

Join a growing community of people making an impact on research from their phones.

Insights. Research. Rewards.

Get doc.ai